

MATERIAL CHANGE NOTICE SUBMISSION DETAILS

MCN Number	2026-07-30-1533
OHCA Review Start Date	September 21, 2026
Anticipated date (unless tolled per regulation) by which OHCA could waive cost and market impact review	November 5, 2026
Anticipated date (unless tolled per regulation) by which OHCA could determine cost and market impact review required	November 20, 2026

SUBMITTER

HEALTH CARE ENTITY CONTACT FOR PUBLIC INQUIRY

Title	CEO
First Name	Troy
Last Name	Simon
Email Address	troy.simon@lahomg.com
Street Address	541 West Colorado
City	Glendale
State	CA
Postal Code	91204

GENERAL

Business Name	Los Angeles Hematology/Oncology Medical Group
Website	https://www.lacancernetwork.com
Ownership Type	Partnership
Tax Status	For-profit
Federal Tax ID	95-4332724
Description of Submitting Organization	Los Angeles Hematology/Oncology Medical Group d/b/a The Los Angeles Cancer Network (LACN) is a California general partnership with separate operating divisions. Each division has a separate division policy agreement and charter for decisions relating only to that division, and subject to the centralized governance of LACN. All partners in LACN are physicians licensed to practice in the state of California. LACN is a community-based, multi-specialty group practice serving patients with cancer and blood, gynecologic, and gastrointestinal disorders across Los Angeles, Riverside, Orange, and San Bernadino counties. Its mission is to provide individualized, patient-centered care using established, evidence-based advances in cancer treatment. LACN's care is delivered by board-certified physicians across medical oncology,

	hematology, gynecologic oncology, and GI, who develop treatment plans tailored to each patient's diagnosis and clinical needs, in coordination with affiliated hospitals. LACN provides a comprehensive range of services, including medical oncology, gynecologic oncology, and GI. Clinical services include the administration of chemotherapy and infusion therapy, as well as on-site oral oncolytic dispensing to support medication access and adherence. The practice also conducts clinical research, offering patients access to early- through late-stage clinical trials (Phases 1, 2, and 3).
Health Care Provider	Yes
For Providers: Desc. of Capacity or Patients served in California	LACN operates 27 clinics across Los Angeles, Riverside, and Orange County. Service Lines: Medical Oncology, Gynecologic Oncology, Gastroenterology, In Office Dispensing, Infusion Number of Staff: LACN has 121 non-clinical and 246 clinical employees including 38 medical oncologists, 7 gynecologic oncologists, 1 gastroenterologist, and 47 advanced practice providers. Number of Patients Served: 32,779 unique patients in Los Angeles County 2025 based on FY2025 charge data by unique patient ID number. 5,232 unique patients in Riverside County 2025 based on FY2025 charge data by unique patient ID number. 1,682 unique patients in San Bernardino County 2025 based on FY2025 charge data by unique patient ID number. 14,873 unique patients in Orange County 2025 based on FY2025 charge data by unique patient ID number.

LOCATIONS

Counties	Los Angeles; Orange; Riverside; San Bernardino
California licenses and numbers	See attached.
Other States Served	None

Primary Languages used when providing services	English; Armenian; Farsi; Spanish
Other language if not listed above	LACN uses language line for other languages.

MATERIAL CHANGE

ADDITIONAL ENTITIES

Business Name	Description of the Organization	Ownership Type	Additional MCN Submission
Center for Cancer and Blood Disorders ("CBCS")	CBCS is a medical oncology group practice. For the avoidance of doubt, while CBCS is a medical practice, it is not a provider or physician organization (or noticing entity) within the meaning of OHCA's statutes or regulations. Its revenues are as follows: FY 2023 Revenue: \$18,253,270 FY2024 Revenue: \$21,743,833 FY2025 Revenue: \$24,375,693	Corporation	No
OneOncology, LLC ("OO")	OO is the parent holding company for an oncology and urology-based administrative services provider. It is not a health care entity or noticing entity as defined under OHCA's implementing statutes and regulations. Its revenues (consolidated with its affiliates) are set forth in the financial statements included in this notice.	Limited Liability Company	No

OneOncology West, LLC ("OO West")	OO West is an oncology and urology-based administrative services provider, which supports LACN with administrative support. Notwithstanding the foregoing, it is not a health care entity or noticing entity as defined under OHCA's implementing statutes and regulations.	Limited Liability Company	No
-----------------------------------	---	---------------------------	----

CRITERIA

A health care entity with annual revenue, as defined in section 97435(d) , of at least \$25 million or that owns or controls California assets of at least \$25 million, or;	Yes
--	-----

CIRCUMSTANCES FOR FILING

The transaction is more likely than not to increase annual California-derived revenue of any health care entity that is a party to the transaction by either \$10 million or more or 20% or more of annual California-derived revenue at normal or stabilized levels of utilization or operation.	Yes
---	-----

TRANSACTION DETAILS

Anticipated Date of Transaction Closure	11/1/2026
Description of the Transaction	See attached.
Submitted to US Department of Justice or Federal Trade Commission?	No
Submitted to Other Agency?	No
Subject to court proceeding	No
Description of current services provided and expected post-transaction impacts on health care services	See description of current services in Section 3 and Section 4 of this notice. See attached description re current community and financial assistance initiatives. LACN accepts Medi-Cal and Medicare patients. The parties do not anticipate any material changes to the criteria described in (A) - (E), inclusive.
Description of Potential Post Transaction Changes	Regarding criteria (A), Stavroula A. Otis, M.D. will become a partner assigned to the CCCMG Division of LACN. LACN will have no other change in ownership, governance, or operational structure. CBCS will stay in

	existence following the closing to collect A/R due to the entity, but the parties anticipate that CBCS' operations will wind down thereafter. Regarding criteria (B), LACN will hire the clinical staff of CBCS as of the closing date. OO West will hire the non-clinical staff of CBCS as of the closing date. The parties anticipate all employees of CBCS will be hired by LACN or OO West, and neither LACN nor OO West will not eliminate any job positions or lay off any current employees due to the proposed transaction. Criteria (C) is inapplicable given that there are no such contracts (and hence there are no anticipated changes). Regarding criteria (D), there are many organizations that provide oncology services in the communities LACN serves, including: City of Hope, UCLA, The Oncology Institute (TOI), Kaiser, Loma Linda, Cedars, Cancer and Blood Specialty Clinic, Providence, and Hoag Clinic. The parties anticipate no immediate changes re the criteria in (D).
--	--

LACN Licenses

A. State Clinical Laboratory Licenses (CA CDPH)

1. **Anaheim (State):** California Clinical Laboratory License, State ID CLM-90011155, effective 11/22/2025, expiring 11/21/2026, issued to LA Hematology Oncology Medical Group / LA Cancer Network at 1801 W Romneya Dr., Suite 203, Anaheim, CA 92801, directed by Ronald Tang, DO.
2. **Burbank (State):** California Clinical Laboratory License, State ID CLM-90004921, effective 09/02/2025, expiring 09/01/2026, issued to LA Hematology Oncology Medical Group at 3808 W Riverside Dr., Suite 302, Burbank, CA 91505, directed by Nubar P. Boghossian.
3. **Century City (State):** California Clinical Laboratory License, State ID CLM-90008025, effective 10/19/2025, expiring 10/18/2026, issued to LA Hematology/Oncology Medical Group at 2080 Century Park E., Suite 1005, Los Angeles, CA 90067, directed by Shahrooz Eshaghian.
4. **Downtown LA – Good Samaritan (State):** California Clinical Laboratory License, State ID CLM-00307892, effective 04/30/2026, expiring 04/29/2027, issued to LA Hematology/Oncology Medical Group at 1245 Wilshire Blvd., Suite 303, Los Angeles, CA 90017, directed by Lasika Seneviratne.
5. **Glendale Eulalia – GM (State):** California Clinical Laboratory License, State ID CLM-00348628, effective 12/16/2025, expiring 12/15/2026, issued to LA Hematology/Oncology Medical Group at 222 Eulalia Street, Suite 100C, Glendale, CA 91204, directed by Nubar Boghossian.
6. **Glendale Wilson – GA 200 (State):** California Clinical Laboratory License, State ID CLM-00322495, effective 01/01/2026, expiring 12/31/2026, issued to LA Hematology/Oncology Medical Group at 1505 Wilson Terrace, Suite 200, Glendale, CA 91206, directed by Boris Bagdasarian.
7. **Pasadena (State):** California Clinical Laboratory License, State ID CLM-00300408, effective 02/04/2026, expiring 02/03/2027, issued to LA Hematology/Oncology Medical Group at 50 Alessandro Pl., Suite 310, Pasadena, CA 91105, directed by Weber Chen.
8. **Van Nuys Vanowen 300 (State):** California Clinical Laboratory License, State ID CLM-00309496, effective 07/31/2025, expiring 07/30/2026, issued to LA Hematology Oncology Medical Group at 15211 Vanowen St., Suite 300, Van Nuys, CA 91405, directed by Sheila Vasan.

B. Federal CLIA Certificates of Compliance (CMS)

1. **Anaheim (CLIA):** CLIA Certificate of Compliance, CLIA ID 05D0867202, effective 03/25/2026, expiring 03/24/2028, issued to LA Hematology Oncology Medical Group at 1801 W Romneya Drive, Suite 203, Anaheim, CA 92801, directed by Ronald Tang; certified for Hematology (Code 400).
2. **Burbank (CLIA):** CLIA Certificate of Compliance, CLIA ID 05D2234830, effective 04/28/2023, expiring 07/31/2026 (per CMS demographic data; certificate face shows 04/27/2025), issued to LA Hematology/Oncology Medical Group at 3808 W Riverside Dr., Suite 302, Burbank, CA 91505, directed by Nubar P. Boghossian; certified for Hematology (Code 400).

3. **Century City (CLIA):** CLIA Certificate of Compliance, CLIA ID 05D0925718, effective 12/17/2025, expiring 12/16/2027, issued to LA Hematology Oncology Medical Group at 2080 Century Park East, Suite 1005, Los Angeles, CA 90067, directed by Shahrooz Eshaghian; certified for Diagnostic Immunology – General Immunology (220), Routine Chemistry (310), Urinalysis (320), Endocrinology (330), and Hematology (400).
4. **Downtown LA (CLIA):** CLIA Certificate of Compliance, CLIA ID 05D0681290, effective 12/12/2023, expiring 07/31/2026 (per CMS demographic data; certificate face shows 12/11/2025), issued to LA Hematology Oncology Med at 1245 Wilshire Blvd., Suite 303, Los Angeles, CA 90017, directed by Lasika Seneviratne, MD; certified for Hematology (Code 400).
5. **Fountain Valley (CLIA):** CLIA Certificate of Compliance, CLIA ID 05D1015130, effective 07/25/2023, expiring 07/31/2026, issued to LA Hematology Oncology Medical Group at 11180 Warner Ave., Suite 351, Fountain Valley, CA 92708, directed by Haresh S. Jhangiani.
6. **Glendale Eulalia – GM (CLIA):** CLIA Certificate of Compliance, CLIA ID 05D2106319, effective 09/15/2024, expiring 09/14/2026, issued to LA Hematology Oncology Med Grp at 222 W. Eulalia St., Suite 100C, Glendale, CA 91204, directed by Nubar P. Boghossian, MD; certified for Hematology (Code 400).
7. **Glendale Wilson – GA 200 (CLIA):** CLIA Certificate of Compliance, CLIA ID 05D0937109, effective 12/13/2023, expiring 07/31/2026, issued to LA Hematology/Oncology Medical Group at 1505 Wilson Terrace, Suite 200, Glendale, CA 91206, directed by Boris Bagdasarian, DO.
8. **Van Nuys Vanowen 300 (CLIA):** CLIA Certificate of Compliance, CLIA ID 05D0698731, effective 03/15/2025, expiring 03/14/2027, issued to LA Hematology Oncology Medical Group at 15211 Vanowen St., Suite 300, Van Nuys, CA 91405, directed by Sheila Vasan, MD; certified for Hematology (Code 400).

C EPA/RCRA Hazardous Materials Site Registrations

1. **Hazardous Materials Registrations – 18 Sites (List 1):** EPA/RCRA hazardous materials site registrations for 18 LA Hematology/Oncology Medical Group locations across Los Angeles, Orange, and Riverside Counties (including Glendale, Anaheim, Valencia, Laguna Hills, Riverside, Fountain Valley, Corona, Pomona, Century City, Burbank, Van Nuys, Mission Hills, Montebello, Torrance, and multiple LA addresses); all Active, generator category either “N” (Non-Generator) or “LQG” (Large Quantity Generator).
2. **Hazardous Materials Registrations – 4 Sites (List 2):** EPA/RCRA hazardous materials site registrations for 4 additional LA Hematology/Oncology Medical Group locations (entries 21–24 of 24 total): Pasadena at 50 Alessandro Pl., Suite 310; Downtown LA at 1245 Wilshire Blvd., Suite 303; Torrance (GOA) at 23600 Telo Ave., Suite 250; and Northridge at 18251 Roscoe Blvd., Suite 101; all Active.

Transaction Description

1. The goals of the transaction

The transaction aims to bring CBCS (operated by Stavroula A. Otis, M.D.) into the OneOncology/LACN platform through an acquisition of the practice's assets and transition of Stavroula A. Otis, M.D. as a partner within LACN's CCCMG Division. This expands the access to medical care for LACN's patients in the Orange County region with Dr. Otis serving as a long-term clinical leader.

2. A summary of terms of the transaction

OneOncology will acquire the non-clinical assets and LACN will acquire the clinical assets of the practice on a cash-free, debt-free basis, with total consideration in cash at close and in deferred cash. Dr. Otis will join LACN as a full-time physician partner in the CCCMG Division.

3. A statement of why the transaction is necessary or desirable

LACN had interest in a partnership with Dr. Otis for several years, viewing her as a respected medical oncologist and future clinical leader in the Orange County area.

See note below re the benefits of this proposed transaction (particularly re LACN's resources being provided to Dr. Otis' practice and continuity of care for Dr. Spector's patients).

4. General public impact or benefits of the transaction, including quality and equity measures and impacts

The existing patients of Dr. Otis will benefit from continuity of care under the same physician while gaining access to LACN's broader collaborative clinical resources, including expanded drug access (e.g., Revlimid and Lenalidomide through LACN's license) and a larger network of oncology specialists. The transition also ensures that Dr. Spector's departing patient panel will continue to be served through LACN-provided physicians, preserving access to oncology care for vulnerable patients in the Orange County community.

5. Narrative description of the expected competitive impacts of the transaction

The transaction is not expected to have a material impact on competition in the California oncology market, as it effectively represents a single physician-owned practice joining a larger physician network rather than a consolidation of competing entities. The practice of Dr. Otis, as a sole-physician operation in Orange, CA, will continue serving the same patient population under LACN's platform without meaningfully altering the competitive landscape in the broader California market.

6. Description of any actions or activities to mitigate any potential adverse impacts of the transaction on the public

Dr. Otis will continue to operate out of the same office and caring for the same patient community after the transaction closes.